parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.10 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in rod photoreceptor cells	0.75
chemistry Open Targets	compounds already reach it: abt-102, zucapsaicin, mavatrep +16	1.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	69 Parkinson's papers of 9,419	0.44
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 2600

receipt 2609: TRPV1 in dopamine neurons, braak

power: full sample +0.00 (p 0.990, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.01 (p 0.962, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.00 (p 0.997, n 18). could be the mix.
skeptic: leave-one-out range -0.14 to +0.10, sign flips 6; without severely affected donors +0.00 (p 0.990, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TRPV1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 2608: TRPV1 in astrocytes, braak

power: full sample +0.02 (p 0.949, n 18), 95% CI -0.45 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.03 (p 0.901, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.01 (p 0.962, n 18). could be the mix.
skeptic: leave-one-out range -0.10 to +0.14, sign flips 7; without severely affected donors +0.02 (p 0.949, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TRPV1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts